Virtus ETF Advisers LLC raised its position in shares of Loxo Oncology Inc (NASDAQ:LOXO) by 63.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,322 shares of the biopharmaceutical company’s stock after purchasing an additional 1,684 shares during the period. Virtus ETF Advisers LLC’s holdings in Loxo Oncology were worth $605,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Loxo Oncology by 11.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,670,023 shares of the biopharmaceutical company’s stock worth $456,119,000 after purchasing an additional 281,635 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Loxo Oncology by 11.8% during the 3rd quarter. Vanguard Group Inc now owns 2,670,023 shares of the biopharmaceutical company’s stock valued at $456,119,000 after acquiring an additional 281,635 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Loxo Oncology by 8.4% during the 3rd quarter. BlackRock Inc. now owns 2,271,428 shares of the biopharmaceutical company’s stock valued at $388,029,000 after acquiring an additional 176,264 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Loxo Oncology by 20.2% during the 3rd quarter. Alliancebernstein L.P. now owns 574,136 shares of the biopharmaceutical company’s stock valued at $98,080,000 after acquiring an additional 96,335 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Loxo Oncology by 62.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 514,600 shares of the biopharmaceutical company’s stock valued at $87,909,000 after acquiring an additional 196,900 shares during the last quarter. 96.42% of the stock is owned by institutional investors.
In other news, Director Avi Z. Naider acquired 725 shares of the firm’s stock in a transaction dated Thursday, December 13th. The shares were bought at an average price of $138.92 per share, with a total value of $100,717.00. Following the acquisition, the director now owns 126,843 shares of the company’s stock, valued at $17,621,029.56. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jennifer Burstein sold 2,500 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, November 27th. The stock was sold at an average price of $147.68, for a total value of $369,200.00. Following the sale, the vice president now directly owns 1,250 shares in the company, valued at approximately $184,600. The disclosure for this sale can be found here. Insiders have sold a total of 64,000 shares of company stock worth $9,061,875 in the last three months. 17.10% of the stock is owned by insiders.
A number of research analysts have recently commented on the company. Zacks Investment Research lowered Loxo Oncology from a “hold” rating to a “sell” rating in a report on Saturday, November 10th. BidaskClub lowered Loxo Oncology from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. William Blair reissued a “buy” rating on shares of Loxo Oncology in a report on Tuesday, November 27th. Leerink Swann lowered Loxo Oncology from an “outperform” rating to a “market perform” rating in a report on Monday, January 7th. Finally, Raymond James assumed coverage on Loxo Oncology in a report on Wednesday, November 14th. They set a “strong-buy” rating and a $235.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $193.46.
LOXO traded up $0.13 during midday trading on Tuesday, reaching $234.63. The company’s stock had a trading volume of 6,386 shares, compared to its average volume of 1,766,540. The firm has a market capitalization of $7.18 billion, a P/E ratio of -44.19 and a beta of 2.51. Loxo Oncology Inc has a twelve month low of $91.21 and a twelve month high of $234.75.
WARNING: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2019/02/12/virtus-etf-advisers-llc-purchases-1684-shares-of-loxo-oncology-inc-loxo.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.